ReviewMedComm2025
The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- Bile Acids and the Gut-X Axis: TCM-Mediated Systemic Protection and Therapeutic Opportunities for Multi-Organ Diseases.Metabolites · 2026Review
- Review
- Novel Insights on Clinical Outcomes Using Integrated Shotgun Metagenomic Profiling of the Gut Microbiome, Resistome, and Host Immune-Inflammatory Response in Hospitalized Patients with Decompensated Cirrhosis.Pathogens (Basel, Switzerland) · 2026Article
- Epistemic compression in large language model explanations of the gut-liver axis.Frontiers in cellular and infection microbiology · 2026Article
- GLUT5-Driven Gut-Liver Axis Injury Mediating Olanzapine-Induced NAFLD and Dapagliflozin Intervention.Drug design, development and therapy · 2026Article
- Microbiome and metabolite signatures for cirrhosis to HCC risk stratification: progress, controversies, and gaps.Frontiers in cellular and infection microbiology · 2026Review
- From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma.Frontiers in cellular and infection microbiology · 2026Review
- Beyond Organ Boundaries: Molecular Mechanisms of Hepatic Encephalopathy and Parkinson's Disease from the Perspective of the Gut-Liver-Brain Axis.Research (Washington, D.C.) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing global burden of liver disease is a growing public health challenge. The gut‒liver axis, a bidirectional communication system between the intestine and liver via the portal circulation and biliary tract, is crucial for maintaining metabolic and immune homeostasis. Dysregulation of the gut‒liver axis has been recognized as a key driver of the pathogenesis of various liver diseases. However, its complex molecular mechanisms and the resulting precision therapeutic strategies remain under investigation. This review elaborates on the core components of the gut‒liver axis and the key mechanisms of gut‒liver axis imbalance in metabolic dysfunction-associated fatty liver disease, alcohol-associated liver disease, cirrhosis, spontaneous bacterial peritonitis, and primary liver cancer. We discuss the core roles of intestinal barrier dysfunction, dysbiosis, liver immune activation, and bacterial metabolite imbalance. Furthermore, we systematically review emerging therapeutic strategies targeting this axis, such as restoring barrier function, correcting dysbiosis, regulating bacterial metabolism, and blocking deleterious signaling. This review provides an integrative perspective on the pathophysiology of liver diseases and highlights the great potential of targeting the gut‒liver axis in translational medicine to improve the treatment paradigm for liver diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.